丰川资本

丰川资本

您现在的位置： 新闻中心

News

News

06/242026 Industry Insight: Northwest China’s Pharma Champion Bets Big on Chinese Innovative Drugs, Secures HK Listing After Seven Years of Steady Growth Through Market Cycles Fontus Capital News
06/052026 Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma Fontus Capital News
05/142026 Degron Therapeutics Closes $40 Million Series A Extension to Support Molecular Glue Degrader Clinical Development Fontus Capital News
05/122026 Degron Therapeutics and MSD Enter Joint Development Collaboration Agreement in Oncology Fontus Capital News
04/272026 Rocbrutinib Included in CSCO Clinical Practice Guidelines Fontus Capital News
03/242026 Keymed’s NewCo Partner Ouro Medicines Enters into Acquisition Agreement with Gilead Sciences to Accelerate Global Development of Potential Best-in-Class TCE CM336/OM336 Fontus Capital News
03/182026 Micot's Class 1 Innovative Drug MT200605 Injection Receives Orphan Drug Designation from the U.S. FDA for Huntington's Disease Fontus Capital News
02/072026 iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004 Fontus Capital News
02/062026 Micot Announces Exclusive Commercialization Licensing Agreement with Everest Medicines to Commercialize MT1013 Fontus Capital News
02/022026 Lupeng Pharmaceutical Initiates Global Phase III Head-to-Head Trial of Rocbrutinib Versus Pirtobrutinib Treatment in Patients with Post-BTKi R/R CLL/SLL (ROCKET-CLL Study) Fontus Capital News